Current trends in molecular diagnostics of chronic myeloid leukemia

Raquel Vinhas, Milton Cordeiro, Pedro Pedrosa, Alexandra R. Fernandes, Pedro V. Baptista

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Nearly 1.5 million people worldwide suffer from chronic myeloid leukemia (CML), characterized by the genetic translocation t(9;22)(q34;q11.2), involving the fusion of the Abelson oncogene (ABL1) with the breakpoint cluster region (BCR) gene. Early onset diagnosis coupled to current therapeutics allow for a treatment success rate of 90, which has focused research on the development of novel diagnostics approaches. In this review, we present a critical perspective on current strategies for CML diagnostics, comparing to gold standard methodologies and with an eye on the future trends on nanotheranostics.

Original languageEnglish
Pages (from-to)1791-1804
Number of pages14
JournalLeukemia & Lymphoma
Volume58
Issue number8
DOIs
Publication statusPublished - 3 Aug 2017

    Fingerprint

Keywords

  • Chronic myeloid leukemia
  • molecular diagnostics
  • nanotheranostics
  • precision medicine

Cite this